Discovery and validation of a blood-based protein signature for early detection of mesothelioma

Discovery and validation of a blood-based protein signature for early detection of mesothelioma

10/3/2012

A multi-institute team of researchers led by scientists at the NYU Langone Medical Center and SomaLogic, Inc., announced today the discovery and validation of a panel of 13 blood-based protein biomarkers that can detect malignant mesothelioma in even the early stages of this rare but deadly cancer. The work, which is based on a new protein measurement technology developed by SomaLogic, is published today in the open-access scientific journal PLOS ONE.

Malignant mesothelioma is a rare but aggressive lung cancer that can develop several decades after exposure to asbestos. Because it is difficult to diagnose, the majority of cases are not discovered until the disease is far advanced, which results in poor prognosis and limited treatment options. The research described in the PLOS ONE study is aimed at finding a non-invasive test to improve mesothelioma surveillance and detection in high-risk (i.e., asbestos-exposed) patients.  By examining the differences in concentrations in over 1000 proteins in the blood of mesothelioma patients as compared to asbestos-exposed individuals without mesothelioma, the researchers were able to identify a “signature” of 13 specific protein changes that, taken together, indicate the presence of the disease even in early stages.

“The development of  a sensitive and specific serum test for mesothelioma would have an immense impact on the quality and quantity of life for those individuals who have been exposed to asbestos, who are living in uncertainty about whether or not they will develop this devastating disease,” said Dr. Harvey Pass, the Stephen E. Banner Professor of Thoracic Oncology, vice chair of research for the Department of Cardiothoracic Surgery and division chief of General Thoracic Surgery at NYU Langone Medical Center,  and senior author of the PLoS ONE study. “We believe this work is a critical step towards the availability of such a test.”

To find the signature of 13 proteins that indicate the presence of mesothelioma, the researchers applied a new proteomics technology called “SOMAscan™” (see “About” below) that allowed them to widely survey the blood-based protein landscape to find particular changes that indicate the presence of the disease. Unlike genomic studies, blood-based proteins provide a real-time “snapshot” of an individual’s state of health and offer the possibility of detecting a variety of diseases and conditions long before the individual experiences clinical symptoms. However, the fast, accurate and cost-effective measurement of the thousands of proteins that exist in the blood across many different concentrations to find the specific changes of interest has only recently become possible with the availability of the SOMAscan technology.

“We are excited about the application of our SOMAscan assay to this critical, unmet medical need, and have been delighted to work with such accomplished and dedicated researchers and clinicians,” said Dr. Rachel Ostroff, Clinical Research Director at SomaLogic and co-first author of the PLoS ONE study. “We are committed to continuing this important collaboration with Dr. Pass and his colleagues, and expanded studies with more patients are already underway.”

Other contributors to this work include researchers from Mt. Sinai Medical Center in New York, the Libby MT Center for Asbestos Related Diseases, the Karmanos Cancer Center in Detroit, and the Cancer Research Center of Hawaii in Honolulu. The full manuscript is available for viewing and download at http://dx.plos.org/10.1371/journal.pone.0046091.


SomaLogic scientists publish protein biomarker analysis of lung cancer

SomaLogic scientists publish protein biomarker analysis of lung cancer

4/11/2012

 

SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples

SOMAscan™ technology identifies significant protein expression level differences in tumors vs. adjacent non-cancerous tissue, confirming known biomarkers and discovering new ones

Boulder, CO – April 11, 2012

In a scientific paper published today in the journal PLoS ONE, researchers from SomaLogic and the University of Washington in Seattle describe the first application of the SOMAscanTM proteomic assay technology to tissue samples. Working with both tumor and non-cancerous lung samples from patients with non-small cell lung cancer (NSCLC), they identified significant expression changes in 36 proteins, including 13 proteins not previously associated with the disease. These findings reveal significant new information about the biology underlying NSCLC, and have implications for improving early diagnosis and treatment.

“Early detection of NSCLC can dramatically improve the prognosis for patients with the disease, as has been shown recently through the use of CT-scans in a high-risk population of heavy smokers,” said Sheri Wilcox, Ph.D., Director of Discovery Sciences at SomaLogic. “However, this approach has a high false-positive rate, which can result in overdiagnosis and unnecessary treatment. We set out to find additional molecular ‘biomarkers’ that would help guide both the use of imaging techniques as well as choosing appropriate treatments.”

In their study, the researchers found 36 protein biomarkers that showed significant expression differences between the tumor tissue and non-cancerous lung tissue samples taken from the same patients. These potential biomarkers were discovered by simultaneously measuring the expression levels of 820 different proteins in all samples examined, using SomaLogic’s SOMAscan proteomic assay. Of these 36 potential biomarkers, thirteen had not previously been associated with NSCLC, providing new biological insights into the disease as well as suggesting potential new therapeutic targets.

In addition to the NSCLC protein biomarker discovery, the scientists also demonstrate the utility of the protein-binding reagents used in SOMAscan for direct visualization of protein expression in tissue sections using standard histopathology techniques. SOMAmer (Slow Off-rate Modified Aptamer) binding reagents bind their respective proteins in a manner similar to—and as effective as—antibodies, but unlike antibodies they can be used in highly multiplexed applications to look at expression differences across thousands of proteins in a single experiment. And as demonstrated in the PLoS ONE paper, SOMAmers can also be used as individual tissue probing agents for pathology studies.

The paper is available at http://dx.plos.org/10.1371/journal.pone.0035157.

About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company’s mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

About SOMAscan™/SOMAmer™
SomaLogic’s proprietary SOMAscan™ proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmer™ (Slow Off-rate Modified Aptamer) reagents. The unique physical properties of SOMAmers empower the accurate detection and measurement of greater than one thousand proteins to date over a large range of concentrations in a small volume of sample, all in a single SOMAscan assay.

Contact:
Fintan R. Steele, Ph.D.
Executive Director of Communications
SomaLogic, Inc.
Phone: 720-214-3080
Email: fsteele@somalogic.com


SomaLogic and HUNT Biosciences announce CV collaboration

SomaLogic and HUNT Biosciences announce CV collaboration

4/10/2012

 

HUNT Biosciences and SomaLogic announce collaboration to validate protein biomarkers of cardiovascular risk

Levanger, Norway and Boulder, CO, USA – April 10, 2012

HUNT Biosciences and SomaLogic, Inc., today announced a new collaboration to advance the clinical use of protein biomarkers, with an initial focus on the validation of biomarkers for the prediction of cardiovascular events such as strokes, heart attacks, and heart failure.

The collaboration will analyze biological samples and clinical data from HUNT Biosciences using SomaLogic’s unique SOMAscan™ proteomic technology. HUNT Biosciences will work with SomaLogic to select and supply samples and accompanying clinical data and selected phenotype information from up to 2000 of the more than 100 000 participants in the large HUNT health study.

“We believe the HUNT health study offers samples and data that will help identify and validate protein biomarkers of high clinical significance,” said Dr. Per A. Foss, CEO of HUNT Biosciences. “SomaLogic has a promising technology and the company shares our vision of the importance of biomarkers to improve healthcare. We believe this collaboration has a significant potential and could be extended to include other medical conditions that will benefit from the discovery and use of well-documented biomarkers”.

“We are delighted to work with HUNT biosciences to develop new diagnostic tools that predict cardiovascular risk,” said Stephen Williams, Chief Medical Officer of SomaLogic. “The clinical sample cohort available through the HUNT health study is among the broadest in the world, and we believe that our technology is uniquely capable of deriving new clinical insights from those samples that can lead to new diagnostics and acceleration of drug discovery and development efforts to the benefit of patients everywhere.”

About HUNT Biosciences
HUNT Biosciences AS (www.huntbiosciences.com) is the commercial arm of HUNT Research Centre. HUNT Biosciences was established in 2007 in order to offer a professional interface with industry and facilitate commercial use of HUNT data and samples, without compromising the trust of the donor population. HUNT Biosciences is a public company owned by the Norwegian University of Science and Technology (NTNU), the Central Norway Regional Health Authority and the North Trøndelag County.

About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company’s mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

About SOMAscan™/SOMAmers™
SomaLogic’s proprietary SOMAscan™ proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmers™ (Slow Off-rate Modified Aptamers). The unique physical properties of SOMAmers empower the accurate detection and measurement of thousands of proteins over a wide range of concentrations in just a few drops of blood (or other tissues), all in a single SOMAscan assay.

For further information please contact:

HUNT Biosciences AS:
Per A. Foss: CEO
E-mail: per.a.foss@huntbiosciences.com
Phone: +47 951 24 048

SomaLogic, Inc.
Fintan R. Steele, Ph.D.
Executive Director of Communications
Email: fsteele@somalogic.com
Phone: +1 720-214-3080


AAAS 2012 Annual Meeting features talk about SOMAscan technology in “Predictive Medicine”

AAAS 2012 Annual Meeting features talk about SOMAscan technology in “Predictive Medicine”

2/17/2012

SomaLogic, Inc., Receives Grand Challenges Tuberculosis Biomarkers Grant

Boulder CO, February 9, 2012

SomaLogic, Inc., announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, an initiative that seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Urs Ochsner, head of the Infectious Diseases Research Group at SomaLogic, will pursue an innovative research project to identify and validate TB biomarkers, titled SOMAmer-based detection of tuberculosis biomarkers.

The Grand Challenges TB Biomarkers program provides funding for groundbreaking research into TB biomarkers for the development of a low-cost, simple to use tool that can quickly and accurately diagnose TB in developing countries.

“There is an urgent need to break through barriers in biomarker research in order to develop a highly-sensitive point-of-care diagnostic to improve identification of active TB cases,” said Chris Wilson, Director of Global Health Discovery at the Bill & Melinda Gates Foundation. “We hope these innovative ideas lead to effective and affordable TB diagnostics that can make an impact on one of the world’s deadliest infectious diseases.”

Dr. Ochsner’s project is one of ten Grand Challenges TB biomarkers grants announced today. “The initial applications of our SOMAscan™ proteomic technology to detect certain protein biomarkers of the tuberculosis bacteria have been highly promising and exciting,” said Dr. Ochsner. “We are both delighted and grateful to the Gates Foundation for their recognition of the potential of this work, and for their support in helping us bring it to the point where it can make a difference in literally millions of lives.”

The most beneficial diagnostic TB test would need to measure both multiple TB bacterial proteins as well as the host proteins involved in the onset and progression of the disease. In addition, it must perform effectively in the conditions in the parts of the world where TB is most often rampant. SomaLogic’s breakthrough proteomic technology, based on protein-detecting reagents called “SOMAmers,” provides clear advantages over current reagents and methods used in TB tests in terms of accuracy, sensitivity, stability (e.g., no need for refrigeration), ease of production and cost: In short, all of the attributes necessary to develop a POC diagnostic device for remote and resource-poor areas of the world.

In line with the Gates Foundation’s Global Access policy, SomaLogic is committed to ensuring that the knowledge gained during this project is promptly and broadly disseminated, and that diagnostic tests that come from this work will be made available and accessible at a reasonable cost to the developing world.

_______

About Grand Challenges in Global Health
The Bill & Melinda Gates Foundation recognizes that solving our greatest global health issues is a long-term effort. Through Grand Challenges in Global Health, the foundation is committed to seeking out and rewarding not only established researchers in science and technology, but also young investigators, entrepreneurs and innovators to help expand the pipeline of ideas to fight diseases that claim millions of lives each year. We anticipate that additional grants will be awarded through the Grand Challenges program in the future.

About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company’s mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

About SOMAscan™/SOMAmers™
SomaLogic’s proprietary SOMAscan™ proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmers™ (Slow Off-rate Modified Aptamers). The unique physical properties of SOMAmers empower the accurate detection and measurement of thousands of proteins over a large range of concentrations in just a few drops of blood (or other tissues), all in a single SOMAscan assay.


SomaLogic receives Gates Foundation Grand Challenges Tuberculosis Biomarkers Grant

SomaLogic receives Gates Foundation Grand Challenges Tuberculosis Biomarkers Grant

2/9/2012

 

SomaLogic, Inc., Receives Grand Challenges Tuberculosis Biomarkers Grant

Boulder CO, February 9, 2012

SomaLogic, Inc., announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, an initiative that seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Urs Ochsner, head of the Infectious Diseases Research Group at SomaLogic, will pursue an innovative research project to identify and validate TB biomarkers, titled SOMAmer-based detection of tuberculosis biomarkers.

The Grand Challenges TB Biomarkers program provides funding for groundbreaking research into TB biomarkers for the development of a low-cost, simple to use tool that can quickly and accurately diagnose TB in developing countries.

“There is an urgent need to break through barriers in biomarker research in order to develop a highly-sensitive point-of-care diagnostic to improve identification of active TB cases,” said Chris Wilson, Director of Global Health Discovery at the Bill & Melinda Gates Foundation. “We hope these innovative ideas lead to effective and affordable TB diagnostics that can make an impact on one of the world’s deadliest infectious diseases.”

Dr. Ochsner’s project is one of ten Grand Challenges TB biomarkers grants announced today. “The initial applications of our SOMAscan™ proteomic technology to detect certain protein biomarkers of the tuberculosis bacteria have been highly promising and exciting,” said Dr. Ochsner. “We are both delighted and grateful to the Gates Foundation for their recognition of the potential of this work, and for their support in helping us bring it to the point where it can make a difference in literally millions of lives.”

The most beneficial diagnostic TB test would need to measure both multiple TB bacterial proteins as well as the host proteins involved in the onset and progression of the disease. In addition, it must perform effectively in the conditions in the parts of the world where TB is most often rampant. SomaLogic’s breakthrough proteomic technology, based on protein-detecting reagents called “SOMAmers,” provides clear advantages over current reagents and methods used in TB tests in terms of accuracy, sensitivity, stability (e.g., no need for refrigeration), ease of production and cost: In short, all of the attributes necessary to develop a POC diagnostic device for remote and resource-poor areas of the world.

In line with the Gates Foundation’s Global Access policy, SomaLogic is committed to ensuring that the knowledge gained during this project is promptly and broadly disseminated, and that diagnostic tests that come from this work will be made available and accessible at a reasonable cost to the developing world.

_______

About Grand Challenges in Global Health
The Bill & Melinda Gates Foundation recognizes that solving our greatest global health issues is a long-term effort. Through Grand Challenges in Global Health, the foundation is committed to seeking out and rewarding not only established researchers in science and technology, but also young investigators, entrepreneurs and innovators to help expand the pipeline of ideas to fight diseases that claim millions of lives each year. We anticipate that additional grants will be awarded through the Grand Challenges program in the future.

About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company’s mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

About SOMAscan™/SOMAmers™
SomaLogic’s proprietary SOMAscan™ proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmers™ (Slow Off-rate Modified Aptamers). The unique physical properties of SOMAmers empower the accurate detection and measurement of thousands of proteins over a large range of concentrations in just a few drops of blood (or other tissues), all in a single SOMAscan assay.


SomaLogic announces collaboration with Novartis

SomaLogic announces collaboration with Novartis

10/18/2011

SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development

Powerful proteomic technology to be applied to biomarker discovery, target discovery and validation, and companion diagnostics

Boulder CO, October 18, 2011

SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis’ drug discovery and development efforts.

“We are excited by this opportunity to work with Novartis’ world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics,” said Larry Gold, CEO of SomaLogic. “We believe that our technology is uniquely able to address the significant drug discovery and development challenges currently faced by biopharmaceutical companies.”

Terms of the agreement were not disclosed.

SomaLogic’s proprietary proteomic platform is built on two decades of painstaking work to develop an entirely new generation of specific protein-binding reagents that would break open protein biomarker discovery and development in order to drive new diagnostic and therapeutic opportunities. At the heart of SomaLogic’s technology are “SOMAmers” (Slow-Offrate Modified Aptamers), an entirely novel class of protein-binding reagents. SOMAmers offer a uniquely powerful combination of specific binding to individual proteins and facile nucleic acid-based quantification, allowing accurate detection and measurement of literally thousands of proteins over a vast range of concentrations in just a few drops of blood or other tissues.